Resumen

DAIMARI, Rahul; KWAPE, Lawrence  y  OYEKUNLE, Anthony A.. Suicidal overdose of dolutegravir: A case report. South. Afr. j. HIV med. (Online) [online]. 2018, vol.19, n.1, pp.1-3. ISSN 2078-6751.  http://dx.doi.org/10.4102/sajhivmed.v19i1.799.

Dolutegravir (DTG) is the most recently introduced integrase inhibitor for the treatment of HIV infection and is preferred for its superior tolerability and efficacy in both new and pre-treated patients, and infrequent drug interactions. Since January 2017, Botswana has adopted a 'treat-all' approach with a DTG-based antiretroviral (ARV) regimen as first-line treatment. We report a 29-year-old man with clinical stage 1 HIV infection who had been started on DTG, tenofovir and emtricitabine eight months prior, and who was admitted following a suicidal overdose of 1500 mg of DTG. He reported only minor symptoms including vomiting, epigastric pain and dizziness; which promptly resolved following supportive treatment. On admission, full blood count, liver function tests and electrocardiography were unremarkable. However, there was a non-progressive increase in serum creatinine. After a month off ARVs, he was successfully restarted on antiretroviral therapy without any serious adverse effect.

        · texto en Inglés     · Inglés ( pdf )